These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 33974403)

  • 21. Immuno-PET: a navigator in monoclonal antibody development and applications.
    van Dongen GA; Visser GW; Lub-de Hooge MN; de Vries EG; Perk LR
    Oncologist; 2007 Dec; 12(12):1379-89. PubMed ID: 18165614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The bioconjugation and radiosynthesis of 89Zr-DFO-labeled antibodies.
    Zeglis BM; Lewis JS
    J Vis Exp; 2015 Feb; (96):. PubMed ID: 25741890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and radiolabeling of chelator-RNA aptamer bioconjugates with copper-64 for targeted molecular imaging.
    Rockey WM; Huang L; Kloepping KC; Baumhover NJ; Giangrande PH; Schultz MK
    Bioorg Med Chem; 2011 Jul; 19(13):4080-90. PubMed ID: 21658962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PET radiometals for antibody labeling.
    Aluicio-Sarduy E; Ellison PA; Barnhart TE; Cai W; Nickles RJ; Engle JW
    J Labelled Comp Radiopharm; 2018 Jul; 61(9):636-651. PubMed ID: 29341227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current Perspectives on
    Yoon JK; Park BN; Ryu EK; An YS; Lee SJ
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560337
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for
    Vugts DJ; Klaver C; Sewing C; Poot AJ; Adamzek K; Huegli S; Mari C; Visser GWM; Valverde IE; Gasser G; Mindt TL; van Dongen GAMS
    Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):286-295. PubMed ID: 27573793
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immuno-PET for Clinical Theranostic Approaches.
    Bailly C; Cléry PF; Faivre-Chauvet A; Bourgeois M; Guérard F; Haddad F; Barbet J; Chérel M; Kraeber-Bodéré F; Carlier T; Bodet-Milin C
    Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28036044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical Research Highlighting Contemporary Targeting Mechanisms of Radiolabelled Compounds for PET Based Infection Imaging.
    Kleynhans J; Sathekge MM; Ebenhan T
    Semin Nucl Med; 2023 Sep; 53(5):630-643. PubMed ID: 37012169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Comprehensive Review of Non-Covalent Radiofluorination Approaches Using Aluminum [
    Fersing C; Bouhlel A; Cantelli C; Garrigue P; Lisowski V; Guillet B
    Molecules; 2019 Aug; 24(16):. PubMed ID: 31394799
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET).
    Shokeen M; Anderson CJ
    Acc Chem Res; 2009 Jul; 42(7):832-41. PubMed ID: 19530674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody Fragment and Affibody ImmunoPET Imaging Agents: Radiolabelling Strategies and Applications.
    Fu R; Carroll L; Yahioglu G; Aboagye EO; Miller PW
    ChemMedChem; 2018 Dec; 13(23):2466-2478. PubMed ID: 30246488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Site-specifically labeled
    Kristensen LK; Christensen C; Jensen MM; Agnew BJ; Schjöth-Frydendahl C; Kjaer A; Nielsen CH
    Theranostics; 2019; 9(15):4409-4420. PubMed ID: 31285769
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Matching Chelators to Radiometals for Positron Emission Tomography Imaging- Guided Targeted Drug Delivery.
    Deng H; Wang H; Li Z
    Curr Drug Targets; 2015; 16(6):610-24. PubMed ID: 26148988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Re-thinking the role of radiometal isotopes: Towards a future concept for theranostic radiopharmaceuticals.
    Notni J; Wester HJ
    J Labelled Comp Radiopharm; 2018 Mar; 61(3):141-153. PubMed ID: 29143368
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Jauw YWS; O'Donoghue JA; Zijlstra JM; Hoekstra OS; Menke-van der Houven van Oordt CW; Morschhauser F; Carrasquillo JA; Zweegman S; Pandit-Taskar N; Lammertsma AA; van Dongen GAMS; Boellaard R; Weber WA; Huisman MC
    J Nucl Med; 2019 Dec; 60(12):1825-1832. PubMed ID: 31147401
    [No Abstract]   [Full Text] [Related]  

  • 36. Designing the magic bullet? The advancement of immuno-PET into clinical use.
    Wright BD; Lapi SE
    J Nucl Med; 2013 Aug; 54(8):1171-4. PubMed ID: 23908265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. (64)Cu- and (68)Ga-Based PET Imaging of Folate Receptor-Positive Tumors: Development and Evaluation of an Albumin-Binding NODAGA-Folate.
    Farkas R; Siwowska K; Ametamey SM; Schibli R; van der Meulen NP; Müller C
    Mol Pharm; 2016 Jun; 13(6):1979-87. PubMed ID: 27145400
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radiometals: towards a new success story in nuclear imaging?
    Brasse D; Nonat A
    Dalton Trans; 2015 Mar; 44(11):4845-58. PubMed ID: 25437643
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of a 3-hydroxypyridin-2-one (2,3-HOPO) Based Macrocyclic Chelator for (89)Zr(4+) and Its Use for ImmunoPET Imaging of HER2 Positive Model of Ovarian Carcinoma in Mice.
    N Tinianow J; Pandya DN; Pailloux SL; Ogasawara A; Vanderbilt AN; Gill HS; Williams SP; Wadas TJ; Magda D; Marik J
    Theranostics; 2016; 6(4):511-21. PubMed ID: 26941844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methods for the Production of Radiolabeled Bioagents for ImmunoPET.
    Arroyo A; Lyashchenko SK; Lewis JS
    Methods Mol Biol; 2024; 2729():117-142. PubMed ID: 38006494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.